Navigation Links
Cephalon Granted Temporary Restraining Order in AMRIX® Patent Litigation

FRAZER, Pa., May 20, 2011 /PRNewswire/ -- Today, the United States District Court for the District of Delaware granted a motion filed by plaintiffs Cephalon, Inc. (NASDAQ: CEPH), and Eurand, Inc., for a Temporary Restraining Order (TRO) enjoining Mylan Pharmaceuticals Inc., and Mylan Inc., from manufacturing, using, offering to sell or selling its cyclobenzaprine hydrochloride extended-release capsules, a generic version of Cephalon's branded product AMRIX®.  The TRO remains in effect pending appeal.

"We are very pleased with the Court's decision to grant our request for a TRO," said Jerry Pappert, Executive Vice President and General Counsel for Cephalon.  "We remain confident in the strength of the patents protecting AMRIX®, and believe we have a strong case on appeal."

About Cephalon

Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas. Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide. The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 150 products in nearly 100 countries. More information on Cephalon and its products is available at

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide the Cephalon current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.


Fritz Bittenbender
610-883-5855 (office)

610-457-7041 (cell)

Natalie de Vane
610-727-6536 (office)
610-999-8756 (cell)

Investor Relations:
Chip Merritt
610-738-6376 (office)

Joseph Marczely
610-883-5894 (office)

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders
2. Cephalon Recommends Shareholders Reject Valeant Nominees
3. Cephalon First Quarter 2011 Earnings Conference Call Tuesday, May 3, 2011 at 5:00 p.m. EDT
4. Cephalon Announces Positive Topline Results From a Phase IV Study of NUVIGIL in Shift Work Disorder
5. Cephalon to Hold Public Memorial Service to Celebrate the Life of Company Founder, Frank Baldino, Jr., Ph.D.
6. Cephalon Mourns the Passing of Founder, Chairman and CEO, Frank Baldino Jr., Ph.D.
7. Cephalon Announces Chairman and CEO to Remain on Medical Leave of Absence Indefinitely
8. Cephalon Reports Record Earnings and Raises 2010 Guidance
9. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
10. Cephalon Announces Chairman and CEO to Take Medical Leave of Absence
11. Cephalon Completes Acquisition of Arana Therapeutics
Post Your Comments:
(Date:11/24/2015)... Mass. (PRWEB) , ... November 24, 2015 , ... ... to maintain healthy metabolism. But unless it is bound to proteins, copper is ... of Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic ...
(Date:11/24/2015)... -- Clintrax Global, Inc., a worldwide provider of clinical research services headquartered ... the company has set a new quarterly earnings record in Q3 ... posted for Q3 of 2014 to Q3 of 2015.   ... , with the establishment of an Asia-Pacific ... United Kingdom and Mexico , with ...
(Date:11/24/2015)... , ... November 24, 2015 , ... The Academy of ... Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the First–Person ... few years. Many AMA members have embraced this type of racing and several new ...
(Date:11/24/2015)... TEL AVIV, Israel , Nov. 24, 2015  Tikcro Technologies Ltd. ... be held on December 29, 2015 at 11:00 a.m. Israel ... & Co., Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... , election of Eric Paneth and Izhak Tamir ... and Rami Skaliter as external directors; , approval of an ...
Breaking Biology Technology:
(Date:11/17/2015)... 17, 2015 Pressure BioSciences, Inc. (OTCQB: PBIO) ... and sale of broadly enabling, pressure cycling technology ("PCT")-based ... today announced it has received gross proceeds of $745,000 ... Placement (the "Offering"), increasing the total amount raised to ... additional closings are expected in the near future. ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing ... reliable analytical tools has been paving the way ... qualitative determination of discrete analytes in clinical, agricultural, ... are being predominantly used in medical applications, however, ... environmental sectors due to continuous emphasis on improving ...
Breaking Biology News(10 mins):